Loading...
Loading...
A recent market report forecasts that the ANCA‑associated vasculitis therapy market will reach USD 537 million by 2035, driven by advancements in targeted therapies, scientific innovation, and the development of drugs that reduce reliance on traditional corticosteroids.
The report highlights a significant increase in early diagnosis of rare autoimmune diseases, leading to greater demand for advanced and personalized treatments. Major pharmaceutical companies in the U.S. and Europe are actively developing new drugs to safely and effectively reduce vasculitis inflammation.
Investment in scientific research and clinical trials is identified as a key factor driving market growth, alongside rising awareness among patients and clinicians regarding new treatment options. Consequently, the vasculitis treatment sector is expected to expand steadily over the next decade, improving patient outcomes globally.
Source:
